Limits...
Clinicopathological and prognostic significance of CD24 overexpression in patients with gastric cancer: a meta-analysis.

Wu JX, Zhao YY, Wu X, An HX - PLoS ONE (2014)

Bottom Line: Correlations between CD24 expression and clinicopathological features and overall survival (OS) were analyzed.The pooled odds ratios (ORs) indicated CD24 expression was associated with tumor depth (OR = 0.45, 95% confidence interval [CI]  = 0.32-0.63; P<0.00001), status of lymph nodes (OR = 0.40, 95% CI = 0.25-0.64; P = 0.0001) and tumor node metastasis (TNM) stage (OR = 0.56, 95% CI = 0.41-0.77; P = 0.0003).Whereas, combined ORs showed that CD24 expression had no correlation with tumor differentiation or Lauren classifications.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China.

ABSTRACT

Objective: The prognostic significance of CD24 expression for survival in patients with gastric cancer remains controversial. We conducted a meta-analysis to investigate the impact of CD24 expression on clinicopathological features and survival outcomes in gastric cancer.

Methods: A comprehensive literature search of the electronic databases PubMed, Embase, Web of Science and China National Knowledge Infrastructure (CNKI; up to April 8, 2014) was performed for relevant studies using multiple search strategies. Correlations between CD24 expression and clinicopathological features and overall survival (OS) were analyzed.

Results: A total of 1,041 patients with gastric cancer from 9 studies were included. The pooled odds ratios (ORs) indicated CD24 expression was associated with tumor depth (OR = 0.45, 95% confidence interval [CI]  = 0.32-0.63; P<0.00001), status of lymph nodes (OR = 0.40, 95% CI = 0.25-0.64; P = 0.0001) and tumor node metastasis (TNM) stage (OR = 0.56, 95% CI = 0.41-0.77; P = 0.0003). The pooled hazard ratio (HR) for OS showed overexpression of CD24 reduced OS in gastric cancer (HR = 1.99, 95% CI = 1.29-3.07, P = 0.002). Whereas, combined ORs showed that CD24 expression had no correlation with tumor differentiation or Lauren classifications.

Conclusion: CD24 overexpression in patients with gastric cancer indicated worse survival outcomes and was associated with common clinicopathological poor prognostic factors.

Show MeSH

Related in: MedlinePlus

Forest plots of CD24 expression and the clinicopathological features of patients with gastric cancer.The squares and horizontal lines correspond to the study- specific OR and 95% CI. The area of the squares reflects the study-specific weight (inverse of the variance). The diamonds represent the pooled OR and 95% CI. The solid vertical line is at the  value (OR = 1). A The relationship between CD24 expression and tumor differentiation. CD24 expression was not related to tumor differentiation (OR = 0.81, 95% CI = 0.43–1.53, P = 0.52). B The relationship between CD24 expression and Lauren classification. CD24 expression was not different in intestinal-type and diffuse-type of gastric adenocarcinoma. (OR = 1.78, 95% CI = 0.66–4.83, P = 0.26). C The relationship between CD24 expression and tumor depth. CD24 expression was associated with tumor depth (OR = 0.45, 95% CI = 0.32–0.63; P<0.00001). D The relationship between CD24 expression and status of lymph node. CD24 expression was associated with status of lymph node (OR = 0.40, 95% CI = 0.25–0.64; P = 0.0001). E The relationship between CD24 expression and TNM staging. CD24 expression was associated with TNM staging of gastric cancer (OR = 0.56, 95% CI = 0.41–0.77; P = 0.0003). G grade; T tumor; N node.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4264770&req=5

pone-0114746-g002: Forest plots of CD24 expression and the clinicopathological features of patients with gastric cancer.The squares and horizontal lines correspond to the study- specific OR and 95% CI. The area of the squares reflects the study-specific weight (inverse of the variance). The diamonds represent the pooled OR and 95% CI. The solid vertical line is at the value (OR = 1). A The relationship between CD24 expression and tumor differentiation. CD24 expression was not related to tumor differentiation (OR = 0.81, 95% CI = 0.43–1.53, P = 0.52). B The relationship between CD24 expression and Lauren classification. CD24 expression was not different in intestinal-type and diffuse-type of gastric adenocarcinoma. (OR = 1.78, 95% CI = 0.66–4.83, P = 0.26). C The relationship between CD24 expression and tumor depth. CD24 expression was associated with tumor depth (OR = 0.45, 95% CI = 0.32–0.63; P<0.00001). D The relationship between CD24 expression and status of lymph node. CD24 expression was associated with status of lymph node (OR = 0.40, 95% CI = 0.25–0.64; P = 0.0001). E The relationship between CD24 expression and TNM staging. CD24 expression was associated with TNM staging of gastric cancer (OR = 0.56, 95% CI = 0.41–0.77; P = 0.0003). G grade; T tumor; N node.

Mentions: The association between CD24 and histological differentiation was investigated in eight studies. The outcomes were significantly heterogeneous (P = 0.0001, I2 = 76%). Therefore, a random-effects model was used for the meta-analysis. The combined OR revealed CD24 expression was not related to tumor differentiation (OR = 0.81, 95% CI = 0.43–1.53, P = 0.52, Fig. 2A).


Clinicopathological and prognostic significance of CD24 overexpression in patients with gastric cancer: a meta-analysis.

Wu JX, Zhao YY, Wu X, An HX - PLoS ONE (2014)

Forest plots of CD24 expression and the clinicopathological features of patients with gastric cancer.The squares and horizontal lines correspond to the study- specific OR and 95% CI. The area of the squares reflects the study-specific weight (inverse of the variance). The diamonds represent the pooled OR and 95% CI. The solid vertical line is at the  value (OR = 1). A The relationship between CD24 expression and tumor differentiation. CD24 expression was not related to tumor differentiation (OR = 0.81, 95% CI = 0.43–1.53, P = 0.52). B The relationship between CD24 expression and Lauren classification. CD24 expression was not different in intestinal-type and diffuse-type of gastric adenocarcinoma. (OR = 1.78, 95% CI = 0.66–4.83, P = 0.26). C The relationship between CD24 expression and tumor depth. CD24 expression was associated with tumor depth (OR = 0.45, 95% CI = 0.32–0.63; P<0.00001). D The relationship between CD24 expression and status of lymph node. CD24 expression was associated with status of lymph node (OR = 0.40, 95% CI = 0.25–0.64; P = 0.0001). E The relationship between CD24 expression and TNM staging. CD24 expression was associated with TNM staging of gastric cancer (OR = 0.56, 95% CI = 0.41–0.77; P = 0.0003). G grade; T tumor; N node.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4264770&req=5

pone-0114746-g002: Forest plots of CD24 expression and the clinicopathological features of patients with gastric cancer.The squares and horizontal lines correspond to the study- specific OR and 95% CI. The area of the squares reflects the study-specific weight (inverse of the variance). The diamonds represent the pooled OR and 95% CI. The solid vertical line is at the value (OR = 1). A The relationship between CD24 expression and tumor differentiation. CD24 expression was not related to tumor differentiation (OR = 0.81, 95% CI = 0.43–1.53, P = 0.52). B The relationship between CD24 expression and Lauren classification. CD24 expression was not different in intestinal-type and diffuse-type of gastric adenocarcinoma. (OR = 1.78, 95% CI = 0.66–4.83, P = 0.26). C The relationship between CD24 expression and tumor depth. CD24 expression was associated with tumor depth (OR = 0.45, 95% CI = 0.32–0.63; P<0.00001). D The relationship between CD24 expression and status of lymph node. CD24 expression was associated with status of lymph node (OR = 0.40, 95% CI = 0.25–0.64; P = 0.0001). E The relationship between CD24 expression and TNM staging. CD24 expression was associated with TNM staging of gastric cancer (OR = 0.56, 95% CI = 0.41–0.77; P = 0.0003). G grade; T tumor; N node.
Mentions: The association between CD24 and histological differentiation was investigated in eight studies. The outcomes were significantly heterogeneous (P = 0.0001, I2 = 76%). Therefore, a random-effects model was used for the meta-analysis. The combined OR revealed CD24 expression was not related to tumor differentiation (OR = 0.81, 95% CI = 0.43–1.53, P = 0.52, Fig. 2A).

Bottom Line: Correlations between CD24 expression and clinicopathological features and overall survival (OS) were analyzed.The pooled odds ratios (ORs) indicated CD24 expression was associated with tumor depth (OR = 0.45, 95% confidence interval [CI]  = 0.32-0.63; P<0.00001), status of lymph nodes (OR = 0.40, 95% CI = 0.25-0.64; P = 0.0001) and tumor node metastasis (TNM) stage (OR = 0.56, 95% CI = 0.41-0.77; P = 0.0003).Whereas, combined ORs showed that CD24 expression had no correlation with tumor differentiation or Lauren classifications.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China.

ABSTRACT

Objective: The prognostic significance of CD24 expression for survival in patients with gastric cancer remains controversial. We conducted a meta-analysis to investigate the impact of CD24 expression on clinicopathological features and survival outcomes in gastric cancer.

Methods: A comprehensive literature search of the electronic databases PubMed, Embase, Web of Science and China National Knowledge Infrastructure (CNKI; up to April 8, 2014) was performed for relevant studies using multiple search strategies. Correlations between CD24 expression and clinicopathological features and overall survival (OS) were analyzed.

Results: A total of 1,041 patients with gastric cancer from 9 studies were included. The pooled odds ratios (ORs) indicated CD24 expression was associated with tumor depth (OR = 0.45, 95% confidence interval [CI]  = 0.32-0.63; P<0.00001), status of lymph nodes (OR = 0.40, 95% CI = 0.25-0.64; P = 0.0001) and tumor node metastasis (TNM) stage (OR = 0.56, 95% CI = 0.41-0.77; P = 0.0003). The pooled hazard ratio (HR) for OS showed overexpression of CD24 reduced OS in gastric cancer (HR = 1.99, 95% CI = 1.29-3.07, P = 0.002). Whereas, combined ORs showed that CD24 expression had no correlation with tumor differentiation or Lauren classifications.

Conclusion: CD24 overexpression in patients with gastric cancer indicated worse survival outcomes and was associated with common clinicopathological poor prognostic factors.

Show MeSH
Related in: MedlinePlus